Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy - PubMed (original) (raw)
Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy
Saskia Schlossarek et al. Basic Res Cardiol. 2012 Jan.
Abstract
Several lines of evidence suggest that alterations of the ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway (ALP) may be involved in cardiac diseases. Little is known, however, in hypertrophic cardiomyopathy (HCM). This study studied these pathways in two mouse models of HCM that mainly differ by the presence or absence of truncated mutant proteins. Analyses were performed in homozygous Mybpc3-targeted knock-in (KI) mice, carrying a HCM mutation and exhibiting low levels of mutant cardiac myosin-binding protein C (cMyBP-C), and in Mybpc3-targeted knock-out (KO) mice expressing no cMyBP-C, thus serving as a model of pure cMyBP-C insufficiency. In the early postnatal development of cardiac hypertrophy, both models showed higher levels of ubiquitinated proteins and greater proteasomal activities. To specifically monitor the degradation capacity of the UPS with age, mice were crossed with transgenic mice that overexpress Ub(G76V)-GFP. Ub(G76V)-GFP protein levels were fourfold higher in 1-year-old KI, but not KO mice, suggesting a specific UPS impairment in mice expressing truncated cMyBP-C. Whereas protein levels of key ALP markers were higher, suggesting ALP activation in both mutant mice, their mRNA levels did not differ between the groups, underlying rather defective ALP-mediated degradation. Analysis of key proteins regulated in heart failure did not reveal specific alterations in KI and KO mice. Our data suggest (1) UPS activation in early postnatal development of cardiac hypertrophy, (2) specific UPS impairment in old KI mice carrying a HCM mutation, and (3) defective ALP as a common mechanism in genetically engineered mice with cardiac hypertrophy.
Similar articles
- Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants.
Sarikas A, Carrier L, Schenke C, Doll D, Flavigny J, Lindenberg KS, Eschenhagen T, Zolk O. Sarikas A, et al. Cardiovasc Res. 2005 Apr 1;66(1):33-44. doi: 10.1016/j.cardiores.2005.01.004. Cardiovasc Res. 2005. PMID: 15769446 - Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities.
Schlossarek S, Mearini G, Carrier L. Schlossarek S, et al. J Mol Cell Cardiol. 2011 Apr;50(4):613-20. doi: 10.1016/j.yjmcc.2011.01.014. Epub 2011 Feb 1. J Mol Cell Cardiol. 2011. PMID: 21291890 Review. - Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
Stöhr A, Friedrich FW, Flenner F, Geertz B, Eder A, Schaaf S, Hirt MN, Uebeler J, Schlossarek S, Carrier L, Hansen A, Eschenhagen T. Stöhr A, et al. J Mol Cell Cardiol. 2013 Oct;63:189-98. doi: 10.1016/j.yjmcc.2013.07.011. Epub 2013 Jul 26. J Mol Cell Cardiol. 2013. PMID: 23896226 - Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hypertrophic cardiomyopathy.
Bahrudin U, Morisaki H, Morisaki T, Ninomiya H, Higaki K, Nanba E, Igawa O, Takashima S, Mizuta E, Miake J, Yamamoto Y, Shirayoshi Y, Kitakaze M, Carrier L, Hisatome I. Bahrudin U, et al. J Mol Biol. 2008 Dec 26;384(4):896-907. doi: 10.1016/j.jmb.2008.09.070. Epub 2008 Oct 7. J Mol Biol. 2008. PMID: 18929575 - Functional alterations of cardiac proteasomes under physiological and pathological conditions.
Tsukamoto O, Minamino T, Kitakaze M. Tsukamoto O, et al. Cardiovasc Res. 2010 Jan 15;85(2):339-46. doi: 10.1093/cvr/cvp282. Epub 2009 Aug 14. Cardiovasc Res. 2010. PMID: 19684034 Review.
Cited by
- Cardiovascular autophagy: crossroads of pathology, pharmacology and toxicology.
Salabei JK, Conklin DJ. Salabei JK, et al. Cardiovasc Toxicol. 2013 Sep;13(3):220-9. doi: 10.1007/s12012-013-9200-8. Cardiovasc Toxicol. 2013. PMID: 23408289 Free PMC article. Review. - The Calcineurin-TFEB-p62 Pathway Mediates the Activation of Cardiac Macroautophagy by Proteasomal Malfunction.
Pan B, Li J, Parajuli N, Tian Z, Wu P, Lewno MT, Zou J, Wang W, Bedford L, Mayer RJ, Fang J, Liu J, Cui T, Su H, Wang X. Pan B, et al. Circ Res. 2020 Jul 31;127(4):502-518. doi: 10.1161/CIRCRESAHA.119.316007. Epub 2020 May 5. Circ Res. 2020. PMID: 32366200 Free PMC article. - Priming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafil.
Zhang H, Wang X. Zhang H, et al. Future Cardiol. 2015 Mar;11(2):177-89. doi: 10.2217/fca.15.3. Future Cardiol. 2015. PMID: 25760877 Free PMC article. Review. - Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy.
Glazier AA, Thompson A, Day SM. Glazier AA, et al. Pflugers Arch. 2019 May;471(5):781-793. doi: 10.1007/s00424-018-2226-9. Epub 2018 Nov 20. Pflugers Arch. 2019. PMID: 30456444 Free PMC article. Review. - The A31P missense mutation in cardiac myosin binding protein C alters protein structure but does not cause haploinsufficiency.
van Dijk SJ, Bezold Kooiker K, Mazzalupo S, Yang Y, Kostyukova AS, Mustacich DJ, Hoye ER, Stern JA, Kittleson MD, Harris SP. van Dijk SJ, et al. Arch Biochem Biophys. 2016 Jul 1;601:133-40. doi: 10.1016/j.abb.2016.01.006. Epub 2016 Jan 9. Arch Biochem Biophys. 2016. PMID: 26777460 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials